"Silymarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A mixture of flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum. It consists primarily of silybin and its isomers, silicristin and silidianin. Silymarin displays antioxidant and membrane stabilizing activity. It protects various tissues and organs against chemical injury, and shows potential as an antihepatoxic agent.
| Descriptor ID |
D012838
|
| MeSH Number(s) |
D03.383.663.283.266.450.268.777 D03.633.100.150.266.450.268.777
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Silymarin".
Below are MeSH descriptors whose meaning is more specific than "Silymarin".
This graph shows the total number of publications written about "Silymarin" by people in this website by year, and whether "Silymarin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Silymarin" by people in Profiles.
-
Zhang Z, Li X, Sang S, McClements DJ, Chen L, Long J, Jiao A, Wang J, Jin Z, Qiu C. A review of nanostructured delivery systems for the encapsulation, protection, and delivery of silymarin: An emerging nutraceutical. Food Res Int. 2022 06; 156:111314.
-
Gilzad-Kohan H, Sani S, Boroujerdi M. Calcitriol Reverses Induced Expression of Efflux Proteins and Potentiates Cytotoxic Activity of Gemcitabine in Capan-2 Pancreatic Cancer Cells. J Pharm Pharm Sci. 2017; 20(0):295-304.
-
Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008 Feb; 47(2):605-12.